Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study.

Manuel Weber David KerstingBurkhard RiemannTim BrandenburgDagmar Führer-SakelFrank GrünwaldMichael Christoph KreisslHenning DralleFrank WeberKurt Werner SchmidKen HerrmannWalter JentzenHong GrafeChristoph RischplerSarah TheurerAndreas BockischJames NagarajahWolfgang P Fendler

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Genotype-guided MAPK inhibition was safe and resulted in successful redifferentiation in about one third of patients in each arm. Subsequent 131I therapy led to a thyroglobulin (Tg) decline in more than half of the treated patients. Low tumor glycolytic rate as assessed by FDG-PET is predictive of redifferentiation success. See related commentary by Cabanillas et al., p. 4164.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
signaling pathway
prognostic factors
peritoneal dialysis
computed tomography
oxidative stress
pet ct
patient reported outcomes
cell proliferation
pet imaging
patient reported